| Utilities | Incremental effectiveness in gained QALYs | ICER in $/QALY | ||||
---|---|---|---|---|---|---|---|
Cabozantinib | BSC | German model | US model | ||||
stable | prog | stable | prog | ||||
0.760 | 0.680 | 0.760 | 0.680 | 0.15 | 375,470 | 1,189,706 | |
Base Case increased by findings of Abou-Alfa et al. [19] | 0.852 | 0.680 | 0.760 | 0.680 | 0.20 | 266,479 | 844,359 |
Cabozantinib as first-line in advanced RCC [29] | 0.817 | 0.777 | 0.817 | 0.777 | 0.15 | 362,825 | 1,149,640 |
0.728 | 0.680 | 0.751 | 0.680 | 0.13 | 427,215 | 1,353,665 | |
Base case with constantly decreasing utility after progressionb | 0.760 | 0.680 | 0.760 | 0.680 | 0.14 | 387,439 | 1,227,631 |